Biotech report card: lots of potential, must try harder
A year ago, Hong Kong’s stock exchange (HKEX) added a new chapter to its regulations, allowing pre-revenue biotechnology companies to list. The historic move has turned the city into the biotech IPO hub of Asia. But its fortune could change if the Mainland’s new Nasdaq-style Shanghai tech board, which offers similar pre-revenue concessions, stems the flow of its primarily Chinese issuers.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: